Atrial Fibrillation Detected by Single Time-Point Handheld Electrocardiogram Screening and the Risk of Ischemic Stroke

Wen Sun; Ben Freedman; Carlos Martinez; Christopher Wallenhorst; Bryan P. Yan

doi:10.1055/a-1588-8867

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2022; 122(02): 286-294
DOI: 10.1055/a-1588-8867

Stroke, Systemic or Venous Thromboembolism

Atrial Fibrillation Detected by Single Time-Point Handheld Electrocardiogram Screening and the Risk of Ischemic Stroke

Wen Sun

¹Department of Medicine and Therapeutics, Division of Cardiology, Prince of Wales Hospital & Heart & Vascular Institute, The Chinese University of Hong Kong, Hong Kong

,

Ben Freedman

²Heart Research Institute, Charles Perkins Centre, University of Sydney, Sydney, Australia

,

Carlos Martinez

³Department of Epidemiology, Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany

,

Christopher Wallenhorst

³Department of Epidemiology, Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany

,

Bryan P. Yan

¹Department of Medicine and Therapeutics, Division of Cardiology, Prince of Wales Hospital & Heart & Vascular Institute, The Chinese University of Hong Kong, Hong Kong

› Institutsangaben

Abstract

Objective We evaluated stroke risk in patients with single time-point screen-detected atrial fibrillation (AF) and the effect of oral anticoagulants (OACs).

Methods Consecutive patients aged ≥65 years attending medical outpatient clinics were prospectively enrolled for AF screening using handheld single-lead electrocardiogram (ECG; AliveCor) from December 2014 to December 2017 (NCT02409654). Repeated screening was performed in patients with >1 visit during this period. Three cohorts were formed: screen-detected AF, clinically diagnosed AF, and no AF. Ischemic stroke risk was estimated using adjusted subdistribution hazard ratios (aSHRs) from multivariate regression and no AF as reference, and stratified according to OAC use.

Results Of 11,972 subjects enrolled, 2,238 (18.7%) had clinically diagnosed AF at study enrollment. The yield of screen-detected AF on initial screening was 2.3% (n = 223/9,734). AF was clinically diagnosed during follow-up in 2.3% (n = 216/9,440) and during subsequent screening in 71 initially screen-negative patients. Compared with no AF, patients with screen-detected AF without OAC treatment had the highest stroke risk (aSHR: 2.63; 95% confidence interval: 1.46–4.72), while aSHR for clinically diagnosed AF without OAC use was 2.01 (1.54–2.62). Among screen-detected AF, the risk of stroke was significantly less with OAC (no strokes in 196 person-years) compared with those not given OAC (12 strokes in 429 person-years), p = 0.01.

Conclusion The prognosis of single time-point ECG screen-detected AF is not benign. The risk of stroke is high enough to warrant OAC use, and reduced by OAC.

Keywords

atrial fibrillation - screening - ischemic stroke

Volltext

Referenzen

References
1 Heeringa J, van der Kuip DA, Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27 (08) 949-953
2 Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013; 44 (11) 3103-3108
3 Krijthe BP, Kunst A, Benjamin EJ. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34 (35) 2746-2751
4 Hindricks G, Potpara T, Dagres N. et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
5 Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4 (02) 369-382
6 Mairesse GH, Moran P, Van Gelder IC. et al; ESC Scientific Document Group. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace 2017; 19 (10) 1589-1623
7 Brieger D, Amerena J, Attia JR. et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Med J Aust 2018; 209 (08) 356-362
8 Lowres N, Olivier J, Chao TF. et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Med 2019; 16 (09) e1002903
9 Curry SJ, Krist AH, Owens DK. et al; US Preventive Services Task Force. Screening for atrial fibrillation with Electrocardiography: US Preventive Services Task Force recommendation statement. JAMA 2018; 320 (05) 478-484
10 Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost 2014; 112 (02) 276-286
11 Boriani G, Laroche C, Diemberger I. et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015; 128 (05) 509.e2-518.e2
12 Siontis KC, Gersh BJ, Killian JM. et al. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm 2016; 13 (07) 1418-1424
13 Benjamin EJ, Go AS, Desvigne-Nickens P. et al. Research priorities in atrial fibrillation screening: a report from a National Heart, Lung, and Blood Institute virtual workshop. Circulation 2021; 143 (04) 372-388
14 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111 (06) 1167-1176
15 Freedman B, Camm J, Calkins H. et al; AF-Screen Collaborators. Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation 2017; 135 (19) 1851-1867
16 Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015; 131 (25) 2176-2184
17 Freedman BS, Lowres N. Asymptomatic atrial fibrillation: the case for screening to prevent stroke. JAMA 2015; 314 (18) 1911-1912
18 Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 2015; 191: 172-177
19 Abdel-Qadir H, Fang J, Lee DS. et al. Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2018; 11 (07) e004580
20 Jaakkola J, Mustonen P, Kiviniemi T. et al. Stroke as the first manifestation of atrial fibrillation. PLoS One 2016; 11 (12) e0168010
21 Martinez C, Wallenhorst C, Rietbrock S, Freedman B. Ischemic stroke and transient ischemic attack risk following vitamin K antagonist cessation in newly diagnosed atrial fibrillation: a cohort study. J Am Heart Assoc 2020; 9 (02) e014376
22 Gibbs HFB, Rosenqvist M, Virdone S. et al; GARFIELD-AF Investigators. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening. Am J Med 2021; 134 (07) 893.e11-901.e11 ; In press
23 Nagata Y, Yamagami T, Nutbeam D, Freedman B, Lowres N. Incremental yield of ECG screening repeated annually over 4 years in an adult Japanese population without prior atrial fibrillation: a retrospective cohort study. BMJ Open 2020; 10 (07) e035650
24 Freedman B, Schnabel R, Calkins H. Opportunistic electrocardiogram screening for atrial fibrillation to prevent stroke. JAMA Cardiol 2019; 4 (02) 91-92
25 Ganesan AN, Chew DP, Hartshorne T. et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 2016; 37 (20) 1591-1602
26 Turakhia MP, Shafrin J, Bognar K. et al. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol 2015; 116 (05) 733-739
27 Proietti M, Farcomeni A, Goethals P. et al; Belgian Heart Rhythm Week Investigators. Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. Eur J Prev Cardiol 2019; 26 (09) 964-972
28 Chen Y, Huang QF, Sheng CS. et al. Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): a prospective multicenter study. PLoS Med 2020; 17 (07) e1003146
29 Lee VW, Tam CS, Yan BP, Man Yu C, Yin Lam Y. Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong. Clin Cardiol 2013; 36 (03) 166-171
30 Hernández Madrid A, Potpara TS, Dagres N. et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace 2016; 18 (03) 463-467
31 Vinereanu D, Lopes RD, Bahit MC. et al; IMPACT-AF investigators. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet 2017; 390 (10104): 1737-1746

Zusatzmaterial

Supplementary Material